Aloxi

Aloxi

palonosetron

Manufacturer:

Mundipharma

Distributor:

DKSH
Concise Prescribing Info
Contents
Palonosetron HCl
Indications/Uses
Prevention of acute & delayed nausea & vomiting associated w/ initial & repeat courses of moderately emetogenic cancer chemotherapy. Prevention of acute nausea & vomiting associated w/ initial & repeat courses of highly emetogenic cancer chemotherapy in adults & ped patients 1 mth to <17 yr.
Dosage/Direction for Use
Adult Single 0.25 mg IV dose administered over 30 sec. To be administered approx 30 min before the start of chemotherapy. Ped 1 mth to <17 yr 20 mcg/kg (max 1.5 mg) IV dose administered over 15 min. Administer approx 30 min before the start of chemotherapy.
Contraindications
Special Precautions
Hypersensitivity to other 5-HT3 receptor antagonists. Serotonin syndrome. Concomitant use w/ SSRIs, serotonin & norepinephrine reuptake inhibitors (SNRIs), MAOIs, mirtazapine, fentanyl, lithium, tramadol & methylene blue IV. Pregnancy & lactation. Neonates <1 mth.
Adverse Reactions
Headache, constipation, diarrhea, dizziness, fatigue, abdominal pain, insomnia.
Drug Interactions
Serotonin syndrome may occur w/ 5-HT3 receptor antagonist & other serotonergic drugs including SSRIs & SNRIs. 
MIMS Class
Antiemetics
ATC Classification
A04AA05 - palonosetron ; Belongs to the class of serotonin (5HT3) antagonists. Used for the prevention of nausea and vomiting.
Presentation/Packing
Form
Aloxi inj 0.25 mg/5 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in